Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04962919

Acronym

LACOG 1818

Enrollment

584

Registered

2021-07-15

Start date

2020-01-14

Completion date

2024-01-31

Last updated

2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Neoplasms, Castration-Resistant

Keywords

Prostatic Neoplasms

Brief summary

Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.

Exclusion criteria

* Diagnosis of localized or locally advanced or metastatic disease sensitive to castration; * Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.

Design outcomes

Primary

Measure	Time frame
Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.	December of 2017

Secondary

Measure	Time frame
To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;	December of 2017
To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;	December of 2017
To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;	December of 2017
To describe the rates of skeletal-related complications	December of 2017
To describe the rate of admissions	December of 2017
To describe the number of lines of treatment that patients have undergone	December of 2017
To describe the presence or absence of treatments bone-directed	December of 2017
To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;	December of 2017
To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;	December of 2017

Countries

Brazil

Contacts

PRINCIPAL_INVESTIGATORFernando Cotait Maluf

Latin American Cooperative Oncology Group

Outcome results